Connexin 43 Deficiency Confers Resistance to Immunotherapy in Lung Cancer via Inhibition of the Cyclic GMP‐AMP Synthase–Stimulator of Interferon Genes Pathway
Yuan Zhang, Yu Gao, Jie Wang, Xiaoming Tan, Yusheng Liang, Weize Yu, Zihua Deng, Jingjing Zhou, Zu Ye, Guoqing Luo · 2024
Read Connexin 43 Deficiency Confers Resistance to Immunotherapy in Lung Cancer via Inhibition of the Cyclic GMP‐AMP Synthase–Stimulator of Interferon Genes Pathway by Yuan Zhang, Yu Gao, Jie Wang, Xiaoming Tan, Yusheng Liang, Weize Yu, Zihua Deng, Jingjing Zhou, Zu Ye, Guoqing Luo (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11598135.txt.
Description
Immune checkpoint inhibitors (ICIs), especially PD‐1 inhibitors, are among the first‐line therapeutic drugs for the treatment of advanced non‐small cell lung cancer (NSCLC). However, most patients are not sensitive to PD‐1 inhibitors, and prolonged exposure can lead to acquired resistance. Thus, it is urgent to elucidate the mechanism underlying the resistance of NSCLC to ICIs.
Catalog record
| CREATOR | Yuan Zhang, Yu Gao, Jie Wang, Xiaoming Tan, Yusheng Liang, Weize Yu, Zihua Deng, Jingjing Zhou, Zu Ye, Guoqing Luo |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |